Results 341 to 350 of about 1,168,781 (390)

Correction to: From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials. [PDF]

Int J Neuropsychopharmacol
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

New England Journal of Medicine, 2023
BACKGROUND Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral ...
S. Wharton, T. Blevins, Lisa E. Connery, J. Rosenstock, Sohini Raha, Rong Liu, Xiaosu Ma, K. Mather, A. Haupt, D. Robins, E. Pratt, C. Kazda, Manige Konig   +12 more
semanticscholar   +1 more source

An orally available non-nucleotide STING agonist with antitumor activity

Science, 2020
Targeting STING for cancer therapy Activation of the STING (stimulator of interferon genes) protein by cyclic dinucleotide metabolites plays a critical role in antitumor immunity.
B. Pan, Samanthi A. Perera, J. Piesvaux, J. Presland, Gottfried K. Schroeder, J. Cumming, B. Trotter, M. Altman, A. Buevich, B. Cash, S. Cemerski, Wonsuk Chang, Yiping Chen, P. Dandliker, Guo Feng, Andrew M Haidle, T. Henderson, James P. Jewell, I. Kariv, Ian Knemeyer, J. Kopinja, Brian M. Lacey, J. Laskey, C. Lesburg, Rui Liang, B. Long, Min Lu, Yanhong Ma, E. Minnihan, Greg O'Donnell, Ryan Otte, Laura Price, L. Rakhilina, B. Sauvagnat, Sharad K Sharma, S. Tyagarajan, Hyun Woo, D. Wyss, Serena Xu, D. J. Bennett, G. Addona   +40 more
semanticscholar   +1 more source

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Hepatology, 2020
We evaluated the safety and efficacy of cilofexor (formerly GS‐9674), a small‐molecule nonsteroidal agonist of farnesoid X receptor, in patients with nonalcoholic steatohepatitis (NASH).
K. Patel, S. Harrison, M. Elkhashab, J. Trotter, R. Herring, S. Rojter, Z. Kayali, V. Wong, S. Greenbloom, S. Jayakumar, M. Shiffman, B. Freilich, E. Lawitz, E. Gane, Eliza Harting, Jun Xu, A. Billin, C. Chung, C. Djedjos, G. Subramanian, R. Myers, M. Middleton, M. Rinella, M. Noureddin   +23 more
semanticscholar   +1 more source

A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists

2023
The Gs-coupled A2A adenosine receptor (A2AAR) has been explored extensively as a pharmaceutical target, which has led to numerous clinical trials. However, only one selective A2AAR agonist (regadenoson, Lexiscan) and one selective A2AAR antagonist (istradefylline, Nouriast) have been approved by the FDA, as a pharmacological agent for myocardial ...
Kenneth A, Jacobson, R Rama, Suresh, Paola, Oliva   +2 more
openaire   +2 more sources

Calcium-Agonists

Journal of Molecular and Cellular Cardiology, 1986
In contrast to nifedipine-like calcium antagonists, calcium agonistic 1,4-dihydropyridines have vasoconstricting and positive inotropic properties. BAY K 8644 has become the prototype of this new class. Its enantiomers show opposite effects on the calcium channel: one acts as a calcium agonist with the pharmacological profile of the racemic compound ...
M, Bechem, M, Schramm
openaire   +2 more sources